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Abstract
About 80% of pancreatic cancer patients have glucose intolerance or frank diabetes. This
observation has led to the following two hypotheses: i. pancreatic cancer causes the associated
diabetes and ii. the conditions associated with diabetes promote the development of pancreatic
cancer. Evidence supporting both hypotheses has been accumulated in previous studies. This article
reviews these studies, especially those that have been conducted recently.
Review
The early symptoms of pancreatic cancer, such as abdom-
inal pain, weight loss, fatigue, jaundice, and nausea, are
nonspecific and may occur late in the course of the disease
[1,2]. As a result, pancreatic cancer is usually diagnosed at
an advanced stage, frequently after the tumor has already
metastasized. Pancreatic cancer is insensitive to pharma-
cological and radiological intervention and often recurs
after apparently curative surgery. All these factors contrib-
ute to the dismal prognosis of the disease [3].
About 80% of pancreatic cancer patients have glucose in-
tolerance or frank diabetes [4,5]. This observation has led
to the following two hypotheses: i. pancreatic cancer caus-
es diabetes and ii. diabetes is a risk factor for the develop-
ment of pancreatic cancer. Numerous studies have been
performed in order to elucidate the relationship between
these two diseases.
Evidence suggesting that pancreatic cancer causes diabe-
tes
The majority of diabetes associated with pancreatic cancer
is diagnosed either concomitantly with the cancer or dur-
ing the two years before the cancer is found [6]; 71% of
the glucose intolerance found in pancreatic cancer pa-
tients is unknown before the cancer is diagnosed [5].
These suggest that recently-developed glucose intolerance
or diabetes may be a consequence of pancreatic cancer
and that recent onset of glucose intolerance or diabetes
may be an early sign of pancreatic cancer. Several studies
have demonstrated that diabetes in pancreatic cancer pa-
tients is characterized by peripheral insulin resistance
[4,5,7]. Insulin resistance is also found in non-diabetic or
glucose intolerant pancreatic cancer patients, though to a
lesser degree [7]. Insulin sensitivity and overall diabetic
state in pancreatic cancer patients who undergo tumor re-
section are markedly improved three months after the sur-
gery [7]. These data suggest that pancreatic tumors are
causally related to the insulin resistance and diabetes seen
in pancreatic cancer patients. In their study of sera from
patients with pancreatic cancer and culture media condi-
tioned by human pancreatic cancer cells, Basso et al.
found a 2030 MW peptide that they considered to be a pu-
tative pancreatic cancer associated diabetogenic factor [8].
A number of investigators have studied insulin resistance
at the organ, tissue, and cellular levels in pancreatic cancer
[7–13]. Studies of the initial steps in the insulin signaling
cascade in human skeletal muscles showed no significant
differences in insulin receptor binding, tyrosine kinase ac-
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pancreatic cancer patients and healthy controls [9]. How-
ever, phosphatidylinositol 3-kinase (PI3-K) activity and
glucose transport, which are located downstream to the
initial insulin signaling steps, were impaired in pancreatic
cancer patients [10]. In addition, glycogen synthase activ-
ity was reduced in skeletal muscles of humans and rodents
with pancreatic carcinoma [9,11] and in isolated rat skel-
etal muscles exposed to human pancreatic tumor extracts
in vitro [7]. These data show that the insulin signaling cas-
cade in skeletal muscle is impaired at multiple steps by
pancreatic cancer.
An Italian group has performed a series of studies to inves-
tigate the effects of pancreatic cancer cells on hepatic insu-
lin sensitivity. When mice were treated with culture
medium conditioned by the human pancreatic cancer cell
line Mia PaCa2, blood glucose was elevated compared to
the control value seen in mice treated with unconditioned
medium [12]. In addition, isolated rat hepatocytes
showed impaired glycolysis when incubated in culture
media conditioned by four human pancreatic cancer cell
lines [13].
Islet dysfunction is another etiological component under-
lying the diabetes associated with pancreatic cancer. Be-
cause the islet mass destroyed by the tumor is only a small
proportion of the whole islet mass, the islet dysfunction is
unlikely to be the result of decreased total islet volume. In
fact, endocrine pancreatic function can be maintained
even with a larger loss of pancreatic islets [14]. Reduced
insulin release is seen in pancreatic cancer patients in re-
sponse to classic stimuli [5,15,16]. Insulin release was
also reduced when isolated rat pancreatic islets were incu-
bated in culture media conditioned by the human pancre-
atic cancer cell lines Panc-1 and HPAF or co-cultured with
Panc-1 and HPAF cells [17,18]. Studies of chemically-in-
duced pancreatic cancer in hamsters found that glucose-
stimulated insulin release was impaired in vivo [19] but
not in isolated perfused pancreata [20]. Ishikawa et al.
found an increase in proinsulin relative to insulin in pan-
creatic cancer patients [21], suggesting that the matura-
tion of proinsulin may also be affected by the tumor.
Islet hormone profiles are changed in the circulation of
pancreatic cancer patients, suggesting that secretion by
different types of islet cells is disrupted by pancreatic can-
cer [22]. Changes in islet hormone concentrations in the
circulation can also be seen in hamsters after induction of
pancreatic cancer [23]. Human pancreatic islets adjacent
to pancreatic carcinoma show morphological abnormali-
ties characterized by abnormal co-localization of islet hor-
mones in islet cells [24].
The diabetogenic potential of islet amyloid polypeptide
(IAPP or amylin) has been investigated by several groups.
IAPP is normally produced in islet beta cells and co-re-
leased with insulin at a constant ratio. In 1994, Permert et
al. found elevated circulating levels of IAPP in patients
with pancreatic cancer [25]. Similar results have been re-
ported in more recent studies by other groups [26,27]. The
islets adjacent to human pancreatic carcinomas show re-
duced IAPP staining. In contrast, the expression of IAPP
mRNA in these islets is unchanged, suggesting normal
production but increased release of IAPP [25].
The molar ratio of IAPP/insulin was increased when rat
pancreatic islets were co-cultured with Panc-1 and HPAF
cells or cultured in media conditioned by these cell lines
[17,18]. The ratio was normalized after the co-cultured
cancer cells were removed [18]. In a similar co-culture
model, Ding et al. found that culture media conditioned
by human pancreatic cancer cells contained a soluble
molecule that selectively enhanced IAPP release from
BRIN-BD11 beta cells [28]. Increased IAPP/insulin ratios
were also seen in rats with azaserine-induced acinar pan-
creatic tumors and in hamsters with ductular pancreatic
tumors induced by carcinogen N-nitrosobis(2-oxopro-
pyl)amine (BOP) [29]. However, exposure of isolated rat
pancreatic islets to hamster pancreatic cancer cells did not
change the secretion of insulin and IAPP [17].
A physiological study of isolated rat pancreatic islets has
shown that endogenous IAPP reduces arginine-stimulated
insulin, glucagon, and somatostatin release [30]. Also, the
improvement in glucose tolerance seen after tumor re-
moval is associated with normalization of IAPP levels in
the circulation [25]. Therefore, the increased IAPP release
seen in pancreatic cancer patients may be responsible, at
least in part, for the islet dysfunction seen in these individ-
uals. However, when IAPP is infused in rats to create cir-
culating concentrations comparable to the circulating
IAPP levels in pancreatic cancer patients, the rats have nor-
mal glucose disposal [31]. Thus, the increased IAPP secre-
tion found in pancreatic cancer patients is unlikely to be
responsible for their peripheral insulin resistance.
Evidence for diabetes as a risk factor for pancreatic cancer
Everhart et al. examined 30 of the epidemiological studies
that have looked at the association between diabetes and
pancreatic cancer and used 20 of them in a meta-analysis
[32]. The pooled relative risk from these studies was 2.1
for diabetes with a duration of at least l year prior to can-
cer diagnosis or death and 2.0 for diabetes with a duration
of at least 5 years [32]. The authors concluded that pancre-
atic cancer could be added to the list of complications of
diabetes [32]. Several epidemiological studies have ana-
lyzed relative risks associated with the different periods of
time after the diagnosis of diabetes and have found a rel-Page 2 of 5
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pancreatic cancer even when the diagnosis of diabetes pre-
ceded death by many years [32–37]. A population-based
case-control study in the United States with 526 incident
cases and 2,153 population controls showed a significant
positive trend (P = 0.016) in risk with increasing years pri-
or to diagnosis of cancer [36]. In other studies, the relative
risk decreased with increasing follow-up time but re-
mained significant [34,35,37]. However, other epidemio-
logical studies have concluded that diabetes is not a risk
factor for pancreatic cancer or else that it is not a risk factor
if recently-diagnosed cases are excluded [6,38–40].
Studies of the relationship between diabetes and pancre-
atic cancer are complicated by the fact that diabetes has
two major forms that are different entities in terms of
pathophysiology [41]. A number of studies have suggest-
ed that Type I diabetes is not associated with an increased
risk for pancreatic cancer [37–39]. Most epidemiological
studies, however, have not distinguished between Type I
and Type II diabetes. It is likely that the large majority of
diabetics in the studies have Type II diabetes because this
form of the disease constitutes 80–90% of the cases and is
typically found in older individuals [32,35,41].
In patients with Type II diabetes (non-insulin-dependent
diabetes), the pancreas is generally exposed to substantial
hyperinsulinemia for years [33], suggesting that insulin
may be involved in the association between long-standing
diabetes and pancreatic cancer. A number of experiments
have tested the hypothesis that insulin may stimulate the
growth of pancreatic cancers. Binding studies have shown
the presence of insulin receptors on pancreatic cancer cells
[42–45]. In vitro studies have shown that insulin pro-
motes growth of the hamster pancreatic cancer cell line
H2T [42], the rat acinar pancreatic cancer cell line AR42J
[45], and numerous human pancreatic cancer cells lines
[44,46–51]. However, the human pancreatic cancer cell
line SOJ-6 was not stimulated by insulin [46], and one of
the studies using PANC-1 cells reported no response to ex-
ogenous insulin [49]. In addition to hyperinsulinemia,
the increased blood glucose and free fatty acids in diabetes
may also promote the growth of pancreatic cancer [52].
The genesis of the cancer is also influenced by the endo-
crine pancreas. In vivo studies concerning the effects of ad-
ministration of exogenous insulin and/or induction of
diabetes on pancreatic cancer have provided inconsistent
data that reflect the complex interactions that may be in-
volved in tumor growth [53–56]. Exogenous insulin sig-
nificantly reduced the induction of benign and malignant
pancreatic lesions in hamsters when given 2 hours before
BOP, but the reduction in incidence was not significant
when insulin was given simultaneously with BOP or 2
hours after BOP [53]. Cancer incidence in hamsters receiv-
ing insulin twice daily starting before BOP administration
and continuing through the experimental period did not
differ significantly from that in controls that received BOP
only [54].
When hamsters were given streptozotocin (SZ) injection
to diminish insulin cells and given insulin from the fol-
lowing day untill the end of the experiment, the inhibi-
tion of carcinogenesis in hamsters receiving
SZ+BOP+insulin treatment was greater than that seen in
the SZ+BOP group, compared to group treated by BOP
only [54]. Hamsters receiving SZ+insulin had significantly
fewer insulinomas than SZ-only animals [54]. Because in-
sulin administration was associated with inhibition of
beta cell regeneration and persistence of severe diabetes in
hamsters treated with SZ [57], the investigators in the SZ/
BOP/insulin study concluded that intact islet cells, rather
than the availability of insulin, are prerequisite for trigger-
ing the neoplastic effects of BOP [54]. The association of
intact islets with pancreatic cancer induction is also
shown in transplantation studies in which tumors devel-
op in the submandibular gland after BOP treatment if
normal islets are transplanted to that site but not when
pancreatic ductal cells, thyroid, heart muscle, or starch are
introduced into the gland [58–60]. Submandibular gland
tumor incidence was not changed when hamsters were
pre-treated with SZ before islet transplantation [60].
A study of pancreatic cancer in hamsters fed a high-fat diet
that potentiated pancreatic cancer provided data suggest-
ing that islet proliferation associated with insulin resist-
ance enhances carcinogenesis [61]. In that study, high-fat-
fed hamsters had elevated insulin levels but normal glu-
cose levels, which was consistent with a state of insulin re-
sistance [61]. The turn-over rate of cells in islets is
significantly increased in the high-fat animals, suggesting
a compensatory islet cell proliferation [61]. Administra-
tion of metformin, starting 2 weeks before the administra-
tion of BOP and continuing throughout the experiment,
normalized insulin concentrations and the rate of islet cell
turnover [61]. Malignant pancreatic lesions were found in
50% of the high-fat/BOP animals and none in the high-
fat/BOP/metformin group (P < 0.05) [61].
Conclusion
Recent studies indicate that there is no simple answer to
the question of which of the two hypotheses stated at the
beginning of this review is right. However, it appears that
these hypotheses are not mutually exclusive, since there is
considerable experimental and epidemiological evidence
in support of both of them. Clearly, the relationships be-
tween pancreatic cancer and alterations in glucose metab-
olism are very complex.Page 3 of 5
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